Regarding the effect of RTX therapy on the levels of LTα, LTβ and the chemokine–chemokine receptor pairs CXCL13–CXCR5 and CXCL12–CXCR4, in patients affected by pSS, no data are currently available in the literature. The gene discussed is CXCR4; the disease is peeling skin syndrome.